{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:46:03Z","timestamp":1782373563234,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773204"],"award-info":[{"award-number":["81773204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802970"],"award-info":[{"award-number":["81802970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073310"],"award-info":[{"award-number":["82073310"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202897"],"award-info":[{"award-number":["82202897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20JC1417900"],"award-info":[{"award-number":["20JC1417900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22QB1405600"],"award-info":[{"award-number":["22QB1405600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004106","name":"East China Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004106","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.biopha.2023.115358","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:12:48Z","timestamp":1692987168000},"page":"115358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia"],"prefix":"10.1016","volume":"166","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2023.115358_bib1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood.2020007897","article-title":"Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia","volume":"137","author":"Xiao","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.biopha.2023.115358_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246246","article-title":"Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia","volume":"13","author":"Aureli","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2023.115358_bib3","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: a Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2023.115358_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115358_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","article-title":"New strategies to treat AML: novel insights into AML survival pathways and combination therapies","volume":"35","author":"Nair","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.biopha.2023.115358_bib6","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.biopha.2023.115358_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2012.01112.x","article-title":"Roles of BCL6 in normal and transformed germinal center B cells","volume":"247","author":"Basso","year":"2012","journal-title":"Immunol. Rev."},{"issue":"19","key":"10.1016\/j.biopha.2023.115358_bib8","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/sj.onc.1202197","article-title":"The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT","volume":"17","author":"Huynh","year":"1998","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.biopha.2023.115358_bib9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1101\/gad.14.14.1810","article-title":"BCoR, a novel corepressor involved in BCL-6 repression","volume":"14","author":"Huynh","year":"2000","journal-title":"Genes Dev."},{"issue":"7836","key":"10.1016\/j.biopha.2023.115358_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41586-020-2925-1","article-title":"Small-molecule-induced polymerization triggers degradation of BCL6","volume":"588","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2023.115358_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/eji.202048864","article-title":"Regulation of the humoral type 2 immune response against allergens and helminths","volume":"51","author":"Haase","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115358_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccr.2005.03.037","article-title":"Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice","volume":"7","author":"Cattoretti","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.biopha.2023.115358_bib13","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1172\/JCI85795","article-title":"Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma","volume":"126","author":"Cardenas","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.biopha.2023.115358_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14728222.2018.1420782","article-title":"BCL6 as a therapeutic target for lymphoma","volume":"22","author":"Leeman-Neill","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"issue":"23","key":"10.1016\/j.biopha.2023.115358_bib15","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1021\/acs.jmedchem.2c01433","article-title":"B-cell lymphoma 6 inhibitors: current advances and prospects of drug development for diffuse large B-cell lymphomas","volume":"65","author":"Gu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2023.115358_bib16","first-page":"38","article-title":"Acute myeloid leukemia: a review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"Rhode Isl. Med. J. (2013)"},{"issue":"6","key":"10.1016\/j.biopha.2023.115358_bib17","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2019001745","article-title":"BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells","volume":"137","author":"Kawabata","year":"2021","journal-title":"Blood"},{"issue":"7347","key":"10.1016\/j.biopha.2023.115358_bib18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Duy","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.115358_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI133090","article-title":"BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors","volume":"131","author":"Guo","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"16","key":"10.1016\/j.biopha.2023.115358_bib20","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","volume":"18","author":"Murphy","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2023.115358_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Hatzi","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2023.115358_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/ni.2543","article-title":"Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms","volume":"14","author":"Huang","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2023.115358_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2021.12.035","article-title":"An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo","volume":"529","author":"Xing","year":"2022","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.biopha.2023.115358_bib24","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41596-020-0310-z","article-title":"Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome","volume":"15","author":"Dziekan","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2023.115358_bib25","doi-asserted-by":"crossref","unstructured":"Basso K., Dalla\u2010Favera RJIr. Roles of BCL6 in normal and transformed germinal center B cells, 2012; 247(1): 172\u2013183.","DOI":"10.1111\/j.1600-065X.2012.01112.x"},{"key":"10.1016\/j.biopha.2023.115358_bib26","doi-asserted-by":"crossref","unstructured":"Wang Y., Luo W., Wang Y.J.Dr. PARP-1 and its associated nucleases in DNA damage response, 2019; 81: 102651.","DOI":"10.1016\/j.dnarep.2019.102651"},{"issue":"4","key":"10.1016\/j.biopha.2023.115358_bib27","article-title":"chemistry m","volume":"28","author":"van Stuijvenberg","year":"2020","journal-title":"Target. DNA Damage Response (DDR) Nat. Compd."},{"issue":"11","key":"10.1016\/j.biopha.2023.115358_bib28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2023.115358_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcp.28996","article-title":"Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation","volume":"235","author":"Wang","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115358_bib30","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2023.115358_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","article-title":"Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"26","key":"10.1016\/j.biopha.2023.115358_bib32","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115358_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7826393","article-title":"Five EMT-Related Gene Signatures Predict Acute Myeloid Leukemia Patient Outcome","volume":"2022","author":"Qi","year":"2022","journal-title":"Dis. Markers"},{"issue":"12","key":"10.1016\/j.biopha.2023.115358_bib34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/17512433.2020.1850255","article-title":"Novel therapies for AML: a round-up for clinicians","volume":"13","author":"Swaminathan","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115358_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","article-title":"Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence","volume":"34","author":"Boyd","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.biopha.2023.115358_bib36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.115358_bib37","article-title":"BCL6 attenuates proliferation and oxidative stress of vascular smooth muscle cells in hypertension","volume":"2019","author":"Chen","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"8","key":"10.1016\/j.biopha.2023.115358_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:46:42Z","timestamp":1782370002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223011496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":38,"alternative-id":["S0753332223011496"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115358","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115358"}}